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Abstract
Background: Adherence to antidepressant treatment is essential for the effective management of patients with
major depressive disorder. Adherence to medication is a dynamic decision-making process, and pharmacists play an
important role in improving adherence to antidepressant treatment in different settings within the healthcare system.
The aim of this study was to assess whether pharmacist interventions based on shared decision making improved
adherence and patient-related outcomes.
Methods: This was a randomised controlled study with a 6-month follow-up. Participants were randomly allocated to
two groups: 1) intervention group (IG) (usual pharmacy services plus pharmacist interventions based on
shared decision making); or 2) control group (CG) (usual pharmacy services). Recruited patients fulfilled the
following inclusion criteria: aged 18 to 60 years diagnosed with a major depressive disorder, and no history
of psychosis or bipolar disorders. A research assistant blinded to the group allocations collected all data.
Results: Two hundred and thirty-nine patients met the inclusion criteria and were randomised to the IG (n = 119) or
CG (n = 120). Nineteen patients dropped out of the study during the follow-up phase. After 6 months, patients in the
IG had significantly more favorable medication adherence, treatment satisfaction, general overuse beliefs, and specific
concern beliefs. However, the groups did not differ in severitye of depression or health-related quality of life after
6 months.
Conclusions: Our findings emphasise the important role of pharmacists in providing direct patient care in regular
pharmacy practice to improve adherence to medications and other patient-reported outcomes.
Trial registration: ISRCTN34879893, Date assigned: 30/12/2014
Background
Medication adherence is a dynamic behaviour that
changes over time with changing beliefs and attitudes
towards prescribed medications, and it reflects a pa-
tient’s effort to optimally manage health, symptoms,
and physical function [1]. Adherence to antidepres-
sant treatment is essential for the effective manage-
ment of major depressive disorder (MDD) [2]. Lack
of adherence affects a large proportion of patients,
with up to 52 % of patients discontinuing medication after
3 months [3]. Recent data from Saudi Arabia have shown
that 53 % of patients have low adherence to antidepressant
medication [4].
Adherence to medication is part of a decision-making
process. Patients actively make decisions about their
medications after weighing their reservations against
the perceived benefits [5]. For each medication, pa-
tients usually consider their respective beliefs about
medication-specific concerns and beliefs about the
need for medications, as well as other general beliefs
[6]. Patients’ authority and their participation in the
decision-making process have increased in the last
two decades [7, 8]. Several terms have arisen to describe
patient involvement, including ‘informed decision mak-
ing’, ‘concordance’, and ‘evidence-based patient choice’ [9].
Furthermore, progressive concepts have developed, such
* Correspondence: khalafaljumaah@yahoo.com
1Department of Pharmacy, Al-Amal Psychiatric Hospital, P.O. Box 33626,
Riyadh 11458, Saudi Arabia
Full list of author information is available at the end of the article
© 2015 Aljumah and Hassali. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Aljumah and Hassali BMC Psychiatry  (2015) 15:219 
DOI 10.1186/s12888-015-0605-8
as shared decision making (SDM). SDM can be de-
fined as ‘a two-way exchange of information, consult-
ation and decision making, where deliberation and
decisions are made by both the healthcare profes-
sional and the patient’ [9, 10].
A systematic review has shown that there is a posi-
tive relationship between patient participation in the
decision-making process and outcomes, satisfaction,
and improved patient self-esteem, alongside decreased
treatment discontinuation rates [11, 12]. Similarly,
positive associations have been found between SDM
involving depressed patients and patient satisfaction
[13]. Additionally, evidence supports the use of deci-
sion aids to improve deliberative treatment decisions
during the SDM process [14].
Depressed patients have demonstrated an interest in
increasing their knowledge about treatment options
and participating in treatment decisions [14, 15]. In
contrast, psychiatrists have shown poor patient involve-
ment when making treatment decisions [16]. Data from
Saudi Arabia showed that the rate of involvement of de-
pressed patients in SDM was 66 %, when measured by ob-
serving patient involvement on the decision-making scale
(OPTION scale). This increased to 79 % when patients
used decision aids [15].
The literature suggests that a patient’s active partici-
pation in decision making regarding treatment for depres-
sion will result in improved adherence, satisfaction, and
improved clinical outcomes. Furthermore, evidence from a
systematic review supports the role of pharmacists in pro-
viding various interventions to improve medication adher-
ence in antidepressant treatment in different settings [4].
The aim of this study was to evaluate the effectiveness
of SDM-based pharmacist intervention for improving
adherence and patient outcomes, compared with usual
care in patients diagnosed with MDD.
Methods
This study followed the Medical Research Council guide-
lines for evaluating complex interventions [17]. We con-
ducted a prospective randomised controlled study with a
6-month follow-up, beginning by randomly grouping
participants into either: 1) the intervention group (IG;
usual pharmacy services plus pharmacist intervention
based on SDM); or 2) the control group (CG; usual phar-
macy services without SDM-based pharmacist interven-
tion). Patients in the control group received usual care
and standard communication regarding their medication
when they visited the pharmacy to collect their antide-
pressants, without any communication aimed specifically
at increasing patients’ involvement, such as in SDM. Any
inquiries addressed to the pharmacist were answered ac-
cording to routine practice in the pharmacy.
SDM intervention
During the intervention, pharmacists followed the SDM
competency framework, which was designed specifically
for depressed patients, to ensure all aspects of SDM
were implemented for each patient [18]. Before the
SDM session started, the research team distributed a
decision aid to patients in the IG. This was developed
and validated by Aljumah and colleagues [15, 19] and is
specifically designed for Arabic-speaking patients [19].
The intervention focused on enhancing patients’ in-
volvement in decision making by assessing their beliefs
and knowledge about antidepressants. The average
duration of the first SDM session (baseline) was
15 min, and the second session (final session) lasted
10 min (at 3-month follow-up).
Setting
The study took place between February 2014 and July
2014 in Riyadh, the capital city of Saudi Arabia. This
city has a total population of more than 5,000,000
and one psychiatric hospital (Al-Amal Hospital; total
of 500 beds) is the main provider of psychiatric care
for the entire population.
Patient populations
Recruited patients fulfilled all of the following inclusion
criteria
Inclusion criteria
 Aged 18 to 60 years;
 Newly diagnosed with an MDD, according to the
criteria of the Diagnostic and Statistical Manual of
Mental Disorders, 4th Ed (DSM-IV; 1994);
 No history of psychosis or bipolar disorders;
 No drug or dependency history;
 No cognitive impairment that may hinder the
assessment.
Patients were excluded from further analysis for the
purpose of this study if they met the following criterion:
Exclusion criteria
 No response at any level to the antidepressant
within 8 weeks of recruitment.
Patients who met the inclusion criteria were briefed
about the aims and objectives of the study and invited to
participate. Written consent was sought within 24 h of
the recruitment visit.
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Data collection
Baseline visits took place in the outpatient clinic, and
assessments were conducted by independent raters (two
trained nurses) who were blinded to patients’ group allo-
cation. This was meant to limit potential observer bias
or conscious deception, and reduce the influence of the
placebo effect. At baseline, the raters recorded data per-
taining to patients’ socio-demographic characteristics,
adherence, beliefs, satisfaction with their depression
treatment, severity of depression, health-related quality
of life, and the quality of patients’ involvement in SDM
during clinical interviews. The same measures were ad-
ministered at the 3- and 6-month follow-up (with the
exception of patient involvement in SDM, which was
not measured at 6 months). Pharmacists and psychia-
trists were not blinded to the patients’ group allocation.
Randomisation
Study participants were individually randomised to one of
two parallel groups with an allocation ratio of 1:1 using a
computer-generated list. The computer-generated alloca-
tion was done by a research assistant with no clinical in-
volvement in the trial. Pharmacists and psychiatrists were
not blinded to the patients’ group allocation but the re-




Direct and indirect measures can be used to evaluate
patients’ medication adherence. In this study, we used
an indirect method, the Morisky Medication Adherence
Scale (MMAS). The MMAS is a well-validated instru-
ment [20–23], with good reliability and an available
Arabic version [24]. The MMAS, which is a useful
screening technique for antidepressant medications [25],
consists of eight items addressing specific medication-
taking behaviours and adherence. MMAS scores range
from 0 to 8, with higher scores representing better ad-
herence. A score of less than 6 is considered to indicate
poor adherence, while a score of 6 or more is considered
to indicate good adherence. Written permission to use
the questionnaire was obtained from its authors.
Assessment of patients’ beliefs about medicine
Patients’ medication-related beliefs were assessed using
the Patients’ Beliefs about Medicine Questionnaire (BMQ;
Specific and General versions). This self-report measure
has proven validity, reliability, and psychometric capability
for both general medical patients and depressed patients
[3, 6, 26]. The BMQ-Specific contains two parts: ‘Specific
Necessity’, which evaluates patients’ views about the ne-
cessity and importance of their medication; and ‘Specific
Concerns’, which questions patients’ beliefs about the
potential harm and adverse effects of their medications.
Each part of the questionnaire has a potential score ran-
ging from 5 to 25. The BMQ-General also has two parts:
‘General Harm’, which measures beliefs that medicines in
general are harmful, addictive or poisonous; and ‘General
Overuse’, which measures beliefs that medicines in general
are overused by doctors [6]. Again, written permission
was obtained from the original author.
Assessment of severity of depression
At each visit, the severity and progression of the disease
was assessed using the Montgomery–Åsberg Depression
Rating Scale (MADRS). The MADRS is an established
scale that is widely used in clinical psychiatry studies to
evaluate depression over time. The MADRS focuses
more on the psychological symptoms of depression, as
opposed to the somatic symptoms [27]. The MADRS
comprises 10 items that cover symptoms typical of
MDD, with a possible score of 0 to 6 for each item. The
total score is a measure of the overall severity of the de-
pression [28, 29]. A score of 30 or more indicates severe
depression, while a score of 10 or below indicates remis-
sion [27, 28].
Assessment of patients’ involvement in decisions
SDM was assessed quantitatively during the baseline and
3-month visits using the Observing Patient Involvement
in Decision-Making scale (OPTION) in the intervention
group only. OPTION was developed to evaluate the ex-
tent to which patients are involved in the clinical
decision-making process [16]. This validated scale con-
sists of 12 rating items, each scored on a five-point
Likert scale (0 to 4). A score of ‘0’ indicates that compe-
tency is not observed and scores of ‘1’ to ‘4’ represent
increasing levels of achievement. An overall OPTION
score is obtained by adding the scores for all 12 items to-
gether (maximum 48), and then standardising it to obtain
a score between 0 and 100 [30]. Trained nurses adminis-
tered the scale using videotapes of SDM interventions.
Assessment of health-related quality of life
Quality of life was assessed using the EQ-5D, a gen-
eric health-related quality of life (HRQoL) instrument
developed by the EuroQoL group. This is a standar-
dised instrument used to measure health outcomes,
which provides a simple descriptive profile and single
index value for health status that can be used in clin-
ical studies [31]. In this study, we used the Arabic
version of the EQ-5D [32]. The first part of the EQ-
5D records self-reported problems in one of five do-
mains (mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression), according to three levels of sever-
ity (no problems, some problems, and extreme problems).
The second part records the subject’s self-assessed health
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on a Visual Analogue Scale (VAS) – a vertical 20 cm line
on which the best and worst health states score 100 and 0,
respectively [32].
Assessment of patient satisfaction with treatment
Patient treatment satisfaction was measured using the
Arabic version of the self-report Treatment Satisfaction
Questionnaire for Medication (TSQM 1.4). The TSQM
has been shown to be psychometrically robust and to
have proven validity and reliability with Arabic patients
[33, 34]. It is a 14-item scale consisting of four dimen-
sions, including effectiveness, side effects, convenience,
and global satisfaction [35]. The patients were instructed
not to respond to the questions in the side effects di-
mension if they were not suffering from side effects.
TSQM 1.4 domain scores range from 0 to 100, with
higher scores representing higher satisfaction in that do-
main [36, 37].
Dropouts
Dropouts were defined as patients who did not attend
the follow-up visits at 3 and 6 months, and who could not
be assessed again. Patients who decided to stop their treat-
ment without having experienced significant side effects
were counted as non-adherents. All analyses were limited
to patients who completed all assessments (complete-case
analysis).
Sample size and power
We needed to obtain a difference of at least 17 points in
the percentage of medication intake at a confidence level
of 95 % [38], allowing for a 20 % dropout rate [39] to
provide 80 % power, assuming an alpha risk of 0.05 and
a beta risk of <0.20. This gave us a target sample size of
195 patients to achieve adequate power.
Data analysis
Descriptive and comparative statistics were analysed
using SPSS. Demographic and clinical characteristics of
the two study groups were compared at baseline using
analysis of variance (continuous variables). ANCOVA
analyses were conducted to assess differences in medica-
tion adherence, beliefs about depression severity, level of
participation in SDM, and satisfaction between treat-
ment groups, controlling for baseline scores. We con-
ducted a mixed ANOVA to analyse changes over time
and between groups. We conducted an independent
sample t-test to compare overall mean adherence be-
tween groups.
Ethical considerations
Approval for the study protocol was received from
the Research Ethics Committee of the Ministry of Health
in Saudi Arabia received before patients recruitment.
Informed written consent was sought from all study par-
ticipants. All participants were provided with a participant
information sheet that included detailed information re-
garding the nature of the study, to enable informed con-
sent. Participants were informed of their right to drop out
of the trial at any stage, without any effects on their treat-
ment or relationship with the treating team. Participants
were assured about confidentiality and data protection of
gathered personal information, which would only be used
by the researchers in an anonymised format.
Results
Two hundred and thirty-nine patients met the inclu-
sion criteria for this study and were randomised to
the IG (n = 119) or the CG (n = 120). Of these, 19 dropped
out of the study during the follow-up phase (Fig. 1) and
were not included in the final analyses. In the group of
drop-outs, there was a greater proportion of males and
elderly patients compared with the group of patients who
completed the study. No other baseline differences existed
between the groups.
Table 1 shows demographic characteristics of the
patients, according to group allocation. There were no sta-
tistically significant differences between the IG and CG in
these variables, including age, education, and number of
prescribed antipsychotics. Table 2 shows scores for clinical
and patient-related outcome measures at baseline. Patients
in the IG and CG reported similarly moderate severe de-
pression, with a mean MADRS score of 22.90 (S.D. 13.27)
and 21.89 (S.D. 12.89), respectively. At baseline, there
were no significant differences between the groups in
terms of beliefs towards antidepressant medications, treat-
ment satisfaction scores or HLQoL.
After 3 months, IG patients had significantly higher
scores than CG patients for beliefs about medicine, treat-
ment satisfaction, and medication adherence (Table 3).
After 6 months, compared with CG patients, IG pa-
tients showed significant differences in adherence to
medication, treatment satisfaction, general overuse be-
liefs, specific concern beliefs, and total general beliefs
about medicines (Table 4). Furthermore, severity of
depression and HRQoL were not significantly change
between IG and CG at the end of six months. Using
T-test: to test the difference between the reading at
baseline & end of six month among participant in IG,
a significantly improved at the end of 6 months in se-
verity of depression 20.65 (11.97) T-value 18.09, and
HRQoL 88.71 (10.77) T-value 25.53.
Discussion
In this study, we examined the impact of SDM-based
pharmacist interventions on patient adherence to anti-
depressant medications and related patient-reported out-
comes. During the study, we observed changes over time
Aljumah and Hassali BMC Psychiatry  (2015) 15:219 Page 4 of 9
in adherence, treatment satisfaction, and beliefs about
antidepressants in the IG but not the CG. After
6 months, IG patients showed statistically significant
increases of up to 18 % in adherence to antidepressants
and 6 % in treatment satisfaction, and a decrease of 8 % in
concern beliefs and general beliefs about medicines.
Our finding of improvements in adherence to antide-
pressants after pharmacist intervention is consistent
with those of other studies (Canales, Bultman, Finley,
Brook, 2005 and Rickles et al., 2005 [40, 4]). Further-
more, consistent with previous studies we did not find
significant differences in the severity of depression be-
tween our groups. Most previous studies that delivered
similar interventions as that described in this paper
have reported no differences in the severity of depres-
sion or depressive symptoms between groups (Capoccia
et al., 2004; Bosmans et al., 2007). Only one study has
reported significant improvements in depressive symp-
toms, using the Hamilton Psychiatric Rating to measure
severity of depression after pharmacist interventions in
acute care psychiatric inpatients [43]. Differences in the
patient sample studied (inpatient versus outpatient) may
explain these differences.
However, a significant negative correlation (−0.327)
between improvements in adherence and severity of de-
pressive symptoms has been reported [44]. In this study,
there were improvements in depression severity in that
we observed improvements in adherence between base-
line and 6 months in IG patients. However, there were
no significant differences between the IG and the CG.
This lack of a significant difference in depression severity
between groups could result from a lack of statistical power,
because the sample was calculated to obtain a difference
in the main outcome (adherence to antidepressants). This
Fig. 1 Recruitment flow diagram
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may mean the study was underpowered to detect endpoint
changes in secondary outcomes, such as the severity of de-
pression. However, in this study, we used a sensitive scale
(MADRS) to detect endpoint changes in depression symp-
toms in response to the treatment of depression [45].
Both groups reported high treatment satisfaction
rates, with IG patients showing significantly greater
satisfaction than did CG patients. This finding is
consistent with a direct positive correlation between
adherence to antidepressants and treatment satisfac-
tion reported elsewhere [46]. It is also similar to find-
ings from another 20 studies reported in a recent
literature review [4, 47]. In contrast, both groups re-
ported a moderate health-related quality of life, with
no significant differences between groups. HRQoL is
influenced by various psychological comorbidities,
with depression being one of the most important of
these [48, 49]. Furthermore, to assess HRQoL we used
the EQ-5D, which is known to be very specific, but
which produces information that lacks sensitivity.
Therefore, it may not detect small changes, especially
as both groups reported moderate scores at baseline.
In this study, after 3 and 6 months we detected signifi-
cantly different scores in the IG for beliefs about antide-
pressants compared with the CG, particularly regarding
general beliefs about medicines, general overuse, and
specific concern beliefs. This is consistent with results
reported elsewhere (Bultman et al., 2002, Rickles et al.,
2005; Aikens et al., 2008). Adherence appears to be in-
fluenced by specific-concern beliefs and overuse beliefs
about antidepressant medications, which is also consist-
ent with findings from other studies [52, 53].
There are some limitations to our study. First, the
study was conducted at one site only (an outpatient
clinic in a psychiatric hospital) and the intervention was
applied by a limited number of hospital pharmacists.
This decreases the generalisability of the results to other
healthcare settings. Nonetheless, our findings are con-
sistent with studies conducted in other settings. Second,
we use subjective methods (self-report scales and ques-
tionnaires) to measure patient outcomes, which may be
subject to bias. However, we selected all scales carefully,
ensuring they were validated with Arabic patients [24,
32, 34, 54]. Furthermore, subjective methods appear
Table 1 Demographic characteristics of intervention group
(n = 110) and control group (n = 110) patients
Intervention group Control group
No (%) No (%)
Sex
Male 49 (44.5) 51 (46.4)
Female 61 (55.5) 59 (53.6)
Age
18–30 years 32 (29.1) 27 (24.5)
31–40 years 31 (28.2) 35 (31.8)
41–50 years 27 (24.5) 27 (24.5)
51–60 years 20 (18.2) 21 (19.1)
Education level
Uneducated 19 (17.3) 31 (28.2)
Primary 17 (15.5) 17 (15.5)
Intermediate 21 (19.1) 23 (20.9)
Secondary 37 (33.6) 29 (26.4)
College/Bachelor 16 (14.5) 10 (9.1)
Number of antidepressants prescribed
One 86 (78.2) 95 (86.4)
Two 24 (21.8) 15 (13.6)
Table 2 Clinical characteristics and outcomes in intervention group and control group patients
Intervention group Control group T-value Sig.
Mean (S.D.) Mean (S.D.)
General overuse 12.42 (2.24) 12.74 (2.63) 0.966 0.335
General harm 11.16 (2.50) 10.88 (2.96) 0.763 0.446
Beneficial effect of pharmaceuticals 14.69 (1.97) 14.96 (2.14) 0.984 0.326
Beliefs about medicines 38.27 (3.92) 38.58 (4.48) 0.545 0.587
Sensitive 15.72 (2.66) 15.55 (3.13) 0.441 0.660
Necessity beliefs 18.19 (3.68) 18.30 (4.19) 0.205 0.838
Concern beliefs 13.07 (3.36) 13.38 (4.04) 0.616 0.538
Treatment Satisfaction Questionnaire for Medication (TSQM) 83.20 (11.42) 82.54 (13.41) 0.396 0.692
Estimated weights for EQ-5D 0.63 (0.37) 0.65 (0.38) 0.414 0.680
Montgomery–Åsberg Depression Scale 22.90 (13.27) 21.44 (12.89) 0.830 0.408
Medication Adherence Scale 5.13 (1.80) 5.19 (2.05) 0.218 0.827
T-test for the difference in the characteristics of the study, according to the level of adherence
Aljumah and Hassali BMC Psychiatry  (2015) 15:219 Page 6 of 9
reliable and correlate with the clinical state of psychiatric
patients in clinical practice [55], and patients reporting
low scores are the most likely to be truthful [53]. Finally,
there is a chance that researchers who were not blind to
intervention group may have biased the results found.
However, as those collecting the data were blind to pa-
tient group allocation we believe this had a minimal ef-
fect on our results.
Despite these limitations, the use of randomised
controlled methods is a strength of this study, ensur-
ing equal distribution of demographic and confound-
ing factors across groups (e.g. age, gender, other
symptoms, and medical problems) [56]. Furthermore,
to the best of our knowledge, this is the first study to
investigate pharmacist interventions with patients with
depression to enhance adherence to medications using
SDM processes.
Further studies are needed to evaluate the cost ef-
fectiveness of this intervention and to compare it with
usual pharmacy services. New approaches must be de-
signed to target depression symptoms in addition to
improving adherence, and to improve our understand-
ing of medication-taking behaviour among depressed
patients.
Conclusion
Pharmacist interventions based on SDM delivered to
depressed patients showed a significant positive effect
on adherence, treatment satisfaction, and patients’ be-
liefs about antidepressants. When compared with patients
provided with usual care, patients given the intervention
had better scores on these outcomes. This finding high-
lights the important role pharmacists could play in provid-
ing direct patient care in regular pharmacy practice to
Table 3 Clinical characteristics and outcomes in intervention group and control group patients after 3 months
Intervention group Control group T-value Sig.
Mean (S.D.) Mean (S.D.)
General overuse 12.17 (2.19) 12.69 (2.62) 1.583 0.115
General harm 10.61 (2.37) 10.77 (2.93) 0.467 0.641
Beneficial effect of pharmaceuticals 14.91 (1.99) 15.11 (2.15) 0.708 0.480
Beliefs about medicines 36.84 (3.77) 38.43 (4.46) 2.855 0.005a
Sensitive 15.40 (2.61) 15.47 (3.11) 0.165 0.869
Necessity beliefs 18.73 (3.78) 18.46 (4.19) 0.509 0.611
Concern beliefs 12.42 (3.18) 13.25 (4.00) 1.694 0.092
Treatment Satisfaction Questionnaire for Medication (TSQM) 86.68 (11.08) 82.82 (13.40) 2.326 0.021a
Estimated weights for EQ-5D 0.66 (0.39) 0.65 (0.38) 0.076 0.939
Montgomery–Åsberg Depression Scale 21.07 (12.21) 21.01 (12.63) 0.036 0.971
Medication Adherence Scale 5.79 (1.89) 5.04 (1.98) 2.880 0.004a
aSignificantly different
Table 4 Clinical characteristics and outcomes in intervention group and control group patients after 6 months
Intervention group Control group T-value Sig.
Mean (S.D.) Mean (S.D.)
General overuse 11.93 (2.15) 12.63 (2.61) 2.197 0.029a
General harm 10.08 (2.25) 10.67 (2.90) 1.687 0.093
Beneficial effect of pharmaceuticals 15.35 (2.04) 15.25 (2.15) 0.356 0.722
Beliefs about medicines 35.36 (3.62) 38.12 (4.43) 5.055 <0.0001a
Sensitive 15.10 (2.56) 15.39 (3.10) 0.769 0.442
Necessity beliefs 19.00 (3.83) 18.50 (4.19) 0.939 0.349
Concern beliefs 12.05 (3.08) 13.14 (3.97) 2.278 0.024
Treatment Satisfaction Questionnaire for Medication (TSQM) 88.71 (10.77) 82.89 (13.40) 3.551 <0.0001a
Estimated weights for EQ-5D 0.68 (0.40) 0.66 (0.38) 0.356 0.722
Montgomery–Åsberg Depression Scale 20.65 (11.97) 20.86 (12.54) 0.129 0.897
Medication Adherence Scale 5.99 (1.88) 4.94 (1.94) 4.059 <0.0001a
aSignificantly different
Aljumah and Hassali BMC Psychiatry  (2015) 15:219 Page 7 of 9
improve the adherence to medications and other patient-
reported outcomes.
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